PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Meropenem and imipenem are broad-spectrum carbapenem antibiotic and are frequently prescribed in critically ill patients with severe infections. These patients show several pathophysiological changes that may alter the carbapenem pharmacokinetic (PK) normally found in other populations. Although the PK of carbapenems has been widely studied, most studies have been conducted on small populations, and clinical outcome data are sparse. Therefore, the aims of this study are (i) describe the population pharmacokinetic parameters of meropenem and imipenem in critically ill subject (ii) evaluate the pharmacodynamic of meropenem and imipenem as a predictor of clinical treatment outcome.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Prince of Songkla University
• Treatments: beta-Lactams; Cilastatin; Imipenem; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, tazobactam drug combination; Sulbactam; Tazobactam

Criteria

Inclusion Criteria:

• age >18 years

• severely ill patient who admitted to medical or surgical intensive care unit who require a treatment with meropenem or imipenem antibiotic

Exclusion Criteria:

• severe renal impairment and require renal replacement therapy

• APACHE II score >30

• History of hypersensitivity to carbapenems

• Pregnancy or breast-feeding female